Abbott Laboratories and St. Jude Medical Inc. have kept analysts' busy this week, sifting through both companies' third quarter financials, looking for the read-through of Tuesday's $1.12 billion deal with Terumo Corp., trying to make heads or tails of Muddy Waters' latest cybersecurity attacks against St. Jude, all the while getting little clarity about the $5.8 billion elephant in the room otherwise known as Alere Inc. And yet, after nearly eight months of turbulence related to Abbott's pending merger with Alere, one of the most surprising takeaways from Abbott's...
Abbott Laboratories and St. Jude Medical Inc. have kept analysts' busy this week, sifting through both companies' third quarter financials, looking for the read-through of Tuesday's $1.12 billion deal with Terumo Corp., trying to make heads or tails of Muddy Waters' latest cybersecurity attacks against St. Jude, all the while getting little clarity about the $5.8 billion elephant in the room otherwise known as Alere Inc.
SILVER SPRING, Md. – Can the development of antimicrobials and susceptibility tests be coordinated more effectively? Yes, according to attendees of an FDA workshop Thursday on challenges and opportunities for getting clearance for antimicrobial susceptibility tests (ASTs) shortly after antimicrobial drug approval. "It takes a village," was a phrase tossed out several times during the event, in which clinicians, laboratory representatives, regulators, and members of the pharmaceutical and medical device industries offered potential solutions. The meeting came about a week after the release of draft guidance that is intended to give the FDA recommendations on...
SILVER SPRING, Md. – Can the development of antimicrobials and susceptibility tests be coordinated more effectively? Yes, according to attendees of an FDA workshop Thursday on challenges and opportunities for getting clearance for antimicrobial susceptibility tests (ASTs) shortly after antimicrobial drug approval.
